Diabetes, heart disease linked by same genes: Study

Image
IANS New York
Last Updated : Sep 05 2017 | 1:32 PM IST

Researchers have identified gene variants that boost the risk of developing Type 2 diabetes and coronary heart disease -- the leading cause of global morbidity and mortality, a finding that points to potential targets for common drugs.

While the study confirmed most of the known diabetes "risk loci"-- sites on the genome where small DNA variations have been linked to altered, usually higher diabetes risk -- the researchers also uncovered 16 new risk factors.

The researchers also identified eight specific gene variants that are strongly linked to altered risk for both diseases.

"Identifying these gene variants linked to both Type 2 diabetes and coronary heart disease risk in principle opens up opportunities to lower the risk of both outcomes with a single drug," said co-senior author Danish Saleheen, Assistant Professor at the University of Pennsylvania in the US.

"From a drug development perspective, it would make sense to focus on those pathways that are most strongly linked to both diseases."

Seven of these gene variants, as expected, appeared to increase risk for both Type 2 diabetes and coronary heart disease risk.

The eighth, a variant of the gene for the cholesterol-transport protein ApoE, turned out to be associated with higher diabetes risk but lower coronary heart disease risk.

On the whole, the genetic link between the diseases appears to work in one direction so that risk genes for Type 2 diabetes are much more likely to be associated with higher coronary heart disease risk than the other way around, the researchers explained in the paper published in the journal Nature Genetics.

There could also be some pathways where pharmacological lowering of one disease increases the risk of the other.

"Using evidence from human genetics, it should be possible to design drugs for Type-2 diabetes that have either beneficial or neutral effects on coronary heart disease risk," Saleheen said.

--IANS

rt/amit/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 05 2017 | 1:22 PM IST

Next Story